• Nyheter
  • Sykdommer
  • Kongresser
  • Samfunnet

Registrer deg for nyhetsbrev

For at du skal få adgang til vårt gratis nyhetsbrev, trenger vi informasjon om din yrkestittel og arbeidsplass - så vi kan verifisere at du får tilgang til de annonsene som nyhetsbrevet inneholder.

Abonner på nyhetsbrev
For at du skal få adgang til vårt gratis nyhetsbrev, trenger vi informasjon om din yrkestittel og arbeidsplass - så vi kan verifisere at du får tilgang til de annonsene som nyhetsbrevet inneholder.
Please enter your name!
Please enter your email!
Arbeidsplass

 

Nyheter fra ESMO

  • Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs Activated CD4 memory T cell abundance and T cell receptor diversity are associated with development of severe immune-related adverse events

    Created on: Jan 27, 2022 | 09:00 am
    Jan 27, 2022 | 09:00 am
  • Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab Than with Chemotherapy in Advanced Endometrial Cancer Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab Than with Chemotherapy in Advanced Endometrial Cancer Findings from the Study 309–KEYNOTE-775 among patients who had disease progression after the receipt of previous systemic platinum-based therapy

    Created on: Jan 26, 2022 | 09:00 am
    Jan 26, 2022 | 09:00 am
  • Death Rates from Ovarian Cancer will Fall in the EU and UK in 2022 [Annals of Oncology Press Release] Death Rates from Ovarian Cancer will Fall in the EU and UK in 2022 [Annals of Oncology Press Release] Death rates from ovarian cancer are predicted to fall by 17% in 2022 in the UK and by 7% in EU countries in 2022 compared to 2017

    Created on: Jan 25, 2022 | 23:15 pm
    Jan 25, 2022 | 23:15 pm
  • A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival in Unselected Patients with mCRPC Whose Disease Progressed on Abiraterone A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival in Unselected Patients with mCRPC Whose Disease Progressed on Abiraterone IMbassador 250 findings indicate that biology associated with response to immune checkpoint inhibition is present in few patients with metastatic castration-resistant prostate cancer

    Created on: Jan 25, 2022 | 09:00 am
    Jan 25, 2022 | 09:00 am
  • Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer PANDA challenge consortium cohort report

    Created on: Jan 24, 2022 | 09:00 am
    Jan 24, 2022 | 09:00 am
Powered by Warp Theme Framework
  • Nyheter
  • Sykdommer
  • Kongresser
  • Samfunnet